Virtue Capital Management LLC Sells 294 Shares of Stryker Corporation $SYK

Virtue Capital Management LLC reduced its stake in Stryker Corporation (NYSE:SYK) by 33.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 587 shares of the medical technology company’s stock after selling 294 shares during the quarter. Virtue Capital Management LLC’s holdings in Stryker were worth $232,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its holdings in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Assetmark Inc. grew its position in shares of Stryker by 28.4% during the 1st quarter. Assetmark Inc. now owns 1,667 shares of the medical technology company’s stock valued at $621,000 after acquiring an additional 369 shares during the period. Arkadios Wealth Advisors increased its stake in shares of Stryker by 495.9% during the 1st quarter. Arkadios Wealth Advisors now owns 4,052 shares of the medical technology company’s stock worth $1,508,000 after purchasing an additional 3,372 shares during the last quarter. MONECO Advisors LLC raised its holdings in shares of Stryker by 5.9% in the 1st quarter. MONECO Advisors LLC now owns 2,156 shares of the medical technology company’s stock worth $802,000 after purchasing an additional 121 shares during the period. Finally, Baker Avenue Asset Management LP lifted its stake in Stryker by 7.7% in the first quarter. Baker Avenue Asset Management LP now owns 1,960 shares of the medical technology company’s stock valued at $730,000 after purchasing an additional 140 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SYK has been the subject of a number of recent research reports. Evercore ISI decreased their target price on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. UBS Group set a $408.00 price objective on Stryker in a research note on Monday, October 13th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Needham & Company LLC restated a “buy” rating and set a $448.00 price target on shares of Stryker in a research note on Friday, November 14th. Finally, Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Price Performance

Shares of NYSE SYK opened at $371.29 on Friday. The firm has a market capitalization of $141.99 billion, a P/E ratio of 49.18, a P/E/G ratio of 2.66 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock’s 50-day simple moving average is $368.90 and its two-hundred day simple moving average is $380.26. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Preston Wendell Wells sold 165 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total transaction of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. This trade represents a 2.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the sale, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.